Tandem Diabetes Care Settles Patent Disputes with Roche

The latest update is out from Tandem Diabetes Care ( (TNDM) ).

On May 21, 2025, Tandem Diabetes Care, Inc. and Roche entities settled patent disputes related to insulin delivery systems, agreeing to terminate pending actions and granting each other non-exclusive licenses for ten years. Additionally, Tandem held its virtual Annual Meeting of Stockholders on the same day, where eight directors were elected, executive compensation was approved, and Ernst & Young LLP was ratified as the independent registered public accounting firm for 2025.

The most recent analyst rating on (TNDM) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Tandem Diabetes Care stock, see the TNDM Stock Forecast page.

Spark’s Take on TNDM Stock

According to Spark, TipRanks’ AI Analyst, TNDM is a Neutral.

Tandem Diabetes Care’s stock is weighted down by financial vulnerabilities and valuation concerns, despite strong revenue growth and positive strategic developments. The most impactful factor is the company’s financial performance, which is currently weak due to high leverage and negative cash flow. Technical analysis and corporate events provide some positive signals, but the overall picture is that of a company with potential but significant financial risks.

To see Spark’s full report on TNDM stock, click here.

More about Tandem Diabetes Care

Tandem Diabetes Care, Inc. operates in the medical device industry, focusing on the development and commercialization of products for people with diabetes. Its primary product is the t:slim X2 insulin pump, which is designed to improve the management of insulin therapy.

Average Trading Volume: 1,908,735

Technical Sentiment Signal: Sell

Current Market Cap: $1.37B

For an in-depth examination of TNDM stock, go to TipRanks’ Stock Analysis page.